RT Journal Article
SR Electronic
T1 Longitudinal serology in SARS-CoV-2 infected individuals in India – a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.04.21251140
DO 10.1101/2021.02.04.21251140
A1 Thiruvengadam, Ramachandran
A1 Chattopadhyay, Souvick
A1 Mehdi, Farha
A1 Desiraju, Bapu Koundinya
A1 Chaudhuri, Susmita
A1 Singh, Savita
A1 Bhartia, Vandita
A1 Kshetrapal, Pallavi
A1 Natchu, Uma Chandra Mouli
A1 Wadhwa, Nitya
A1 Sopory, Shailaja
A1 Wahi, Mudita
A1 Pandey, Anil K.
A1 Das, Asim
A1 Anand, Nidhi
A1 Sharma, Nandini
A1 Sharma, Pragya
A1 Saxena, Sonal
A1 Sindhu, Deepa
A1 Sindhu, Brahmdeep
A1 Sharma, Dharmendra
A1 Dang, Navin
A1 Batra, Gaurav
A1 Kang, Gagandeep
A1 Bhatnagar, Shinjini
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.04.21251140.abstract
AB Clinical and epidemiological characteristics of SARS-CoV-2 infection are now widely available, but there are few data on longitudinal serology in large cohorts, particularly from low-and middle-income countries. We established an ongoing prospective cohort of 3840 SARS-CoV-2 RT-PCR positive individuals in the Delhi-National Capital Region of India, to document clinical and immunological characteristics during illness and convalescence. The IgG responses to the receptor binding domain (RBD) and nucleocapsid were assessed at 0-7, 10-28 days and 6-10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates in the post-infection windows of 0–7 days, 10–28 days and 6–10 weeks were 46%, 84.7% and 85.3% respectively (n=782). The proportion with a serological response increased with severity of COVID-19 disease. All participants with severe disease, 89.6% with mild to moderate infection and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values in the nasopharyngeal viral RNA RT-PCR in a subset of asymptomatic and symptomatic seroconverters were comparable (p value: 0.48), with similar results among non-seroconverters (p value: 0.16) (n=169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 infection over a period of ten weeks from South Asia. The low seropositivity in asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.Summary We measured anti-SARS-CoV-2 RBD and NC protein IgG in a multi-hospital-based prospective cohort from northern India up to ten weeks post-infection. The lower seroconversion rate among asymptomatic RT-PCR positive participants has public health significance particularly for interpreting community seroprevalence estimates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Department of Biotechnology, Government of India [BT/PR40401/BIOBANK/03/2020] and Ind-CEPI- Coalition for Epidemic Preparedness Innovations [102/IFD/SAN/5477/2018-2019].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institute Ethics Committees of all participating institutions. Translational Health Science and Technology Institute THS 1.8.1/ (91) dated 13th April 2020; ESIC Medical College Hospital, Faridabad 134/A/11/16/academics/mc/2016/133, dated 15th April 2020 and Loknayak Hospital, New Delhi e-approval dated: Apr 21, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript will be available on request after peer-reviewed publication, upon request to the corresponding author